Mobile

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid® in Adults with Type 1 Diabetes

Mise à jour : Il y a 4 ans
Référence : U1111-1118-2480

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To confirm the effect of continuous subcutaneous insulin infusion (CSII) treatment with faster-acting insulin aspart in terms of glycaemic control by comparing it to CSII treatment with NovoRapid®, in adults with Type 1 Diabetes Mellitus (T1DM), using a non-inferiority approach

Critère d'inclusion

  • Diabetes Mellitus, Type 1

Liens